Trevi Therapeutics Goes Up Against Cara In Itch
This article was originally published in Scrip
Trevi Therapeutics has announced positive Phase II/III results for its lead product nalbuphine ER tablets in treating uremic pruritus.
You may also be interested in...
Finance Watch: Turning Point Launches IPO, Stock Rises 60% On First Day
Public Company Edition: Turning Point's offering priced at $18 and its stock closed at $28.90. Also, Achaogen's bankruptcy reflects difficult antibacterial market, Ophthotech's name change follows strategy shift, and Gilead lays off 150 sales reps. Plus, cell and gene therapy FOPOs flourish.
Keeping Track: FDA's Review Actions Carry On During Shutdown
The latest drug development news and highlights from our US FDA Performance Tracker.
Cara’s Partnership With Vifor Fresenius Provides Validation For Pruritis Drug Korsuva
A Vifor Fresenius joint venture will market Korsuva for CKD-associated pruritis to Fresenius dialysis centers in Europe, and also will do a co-promotion with Cara in the US that may provide a significant head start for the drug.